Ozempic manufacturer Novo Nordisk said patient safety is a priority and “the benefit-risk profile of semaglutide remains ...
Investor's Business Daily on MSN37m
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage ListHims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback